Dx IPOs Plummet, SPAC Market Recedes Among Macroeconomic Difficulties
Managing Director’s Oded Ben-Joseph, PhD, and Paul Mieyal, PhD, were interviewed by 360Dx for their views on capital markets’ current receptiveness towards COVID diagnostics companies and the viability of SPAC’s for life sciences firms.
Article By Kelsy Ketchum / July 12, 2022
Managing Director’s Oded Ben-Joseph, PhD, and Paul Mieyal, PhD, were interviewed by 360Dx for their views on capital markets’ current receptiveness towards COVID diagnostics companies and the viability of SPAC’s for life sciences firms.
Contact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2023. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy
